Novartis Venture Fund previously backed Switzerland-based biotechnology company NovImmune that has just raised $21m.
Switzerland-based biotechnology company NovImmune, which has previously been backed by drugs company Novartis, has raised SFr20m ($21m). Local private bank BZ Bank Aktiengesellschaft led the round following the company’s antibody licensing deal with drugs company Genentech, part of Swtizerland-based Hoffman-La Roche, in July.
In May last year, NovImmune raised SFr62.5m from BZ on behalf of its private clients and hired Penelope Ward from Roche to be its chief medical officer. In 2007, Eduard Holdener, former head of global pharmaceutical development…
